



Protective and therapeutic effects of cannabis plant extract on liver cancer induced by dimethylnitrosamine in mice



Neveen Abd El Moneim Hussein ^{a,*}, Mervat Abd El-Fattah El-Toukhy ^a,
Amany Hussein Kazem ^b, Mahmoud El-Said Ali ^c, Mohammad Abd El-Rahman
Ahmad ^d, Hossam Mahmoud Rashad Ghazy ^a, Ahmed Mohamed Gamal El-Din ^a

^a Applied Medical Chemistry, Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

^b Department of Pathology, Medical Research Institute, University of Alexandria, Alexandria, Egypt

^c Toxicology Department, Forensic Science College, Naif Arab University for Security Sciences, Saudi Arabia

^d Clinical Pathology Department, Medical Military Academy, Alexandria, Egypt

Received 26 December 2013; accepted 19 February 2014

Available online 23 May 2014

KEYWORDS

Hepatocellular carcinoma;
Cannabis;
mTERT;
Caspase-8

Abstract Hepatocellular carcinomas will emerge as a major form of malignancy in the coming decades. When these tumors are in advanced stages, few therapeutic options are available. Therefore, it is essential to search for new treatment modalities to fight this disease.

Aim: Evaluate the possible protective and therapeutic effects of Cannabis extract on dimethylnitrosamine (DMNA)-induced hepatocarcinogenicity in mice.

Methods: Seventy-five male mice were divided into five groups of 15 each: group I mice received corn oil only as the control group; group II mice were injected intraperitoneally with DMNA (10 µg/kg body weight) weekly for 12 weeks; group III mice were pretreated orally with cannabis extract (0.5 ml/kg body weight) every other day for two weeks before the injection of DMNA, and continued until the end of the experiment (12 weeks); group IV mice were treated orally with cannabis extract every other day simultaneously with DMNA injection and continued until the end of the experiment; group V mice were treated orally with cannabis extract every other day after receiving the last intraperitoneal injection of DMNA. A real time PCR was used to quantify telomerase reverse transcriptase and caspase-8 m-RNA expression level.

Abbreviations: HCC, hepatocellular carcinoma; hTERT, human telomerase reverse transcriptase; hTR, human telomerase RNA; CND, cannabinoids; Δ⁹THC, tetrahydrocannabinol; CBD, cannabidiol; DMNA, dimethylnitrosamine.

* Corresponding author. Address: Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, 165 El Hadra Avenue, Alexandria, Egypt. Tel.: +20 122 3667426.

E-mail addresses: neveen39@yahoo.com (N.A.E.M. Hussein), medhatanwar@gmail.com (M.A.E.-F. El-Toukhy), amanikazem@hotmail.com (A.H. Kazem), mahtox2007@yahoo.com (M.E.-S. Ali), mohammad_rhman1963@yahoo.com (M.A.E.-R. Ahmad), Semo_abdo@yahoo.com (H.M.R. Ghazy), dr.biochemist@ymail.com (A.M.G. El-Din).

Peer review under responsibility of Alexandria University Faculty of Medicine.

<http://dx.doi.org/10.1016/j.ajme.2014.02.003>

2090-5068 © 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.

Results: As compared to the control group, mTERT mRNA expression level was significantly increased in group II. The gene in groups (III, IV, and V) was insignificantly higher than the control group but it was significantly decreased as compared to group II. The caspase-8 mRNA expression level was significantly decreased in all groups as compared to the control group. As compared to group II, caspase-8 mRNA level was significantly increased in group III.

Conclusion: The protective effect of cannabis extract is more pronounced in group taking cannabis before DMNA. Cannabinoids might exert their anti-tumor effects by the direct induction of apoptosis and can decrease telomerase activity by inhibiting the expression of the TERT gene. Coordination between inhibition of telomerase activity and induction of apoptosis might be a potential therapeutic agent for cancer treatment.

© 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common solid tumors and the third leading cause of cancer-related death worldwide.¹ Its prognosis remains reserved, with a 5-year survival rate of <5%.² Hepatocarcinogenesis is a multi-step process involving different genetic alterations that ultimately lead to malignant transformation of the hepatocytes.^{3,4} One of the molecular events that underlie the multigenetic process of hepatocarcinogenesis is the activation of human telomerase reverse transcriptase (hTERT) which is normally suppressed in most human somatic tissues after birth.^{5,6}

The replicative potential of eukaryotic cells is regulated through specialized DNA structures called telomeres, which cap the ends of the chromosomes. Telomerase is a ribonucleoprotein complex composed of two essential components: a catalytic subunit with reverse transcriptase activity (hTERT) and RNA subunit with human telomerase RNA (hTR). In the adult organism, telomerase expression is restricted to a few cell types, most notably germ cells and stem/progenitor cells. Telomerase has been a target of increasing interest because high telomerase activity is one of the mechanisms that sustain the unlimited growth of cancer cells.^{7,8} The hTERT gene encodes the catalytic subunit of telomerase, which mediates pleiotropic effects, including the regulation of senescence and proliferation and plays an important role in carcinogenesis.⁹

Programed cell death (apoptosis) is a potent mechanism that limits the expansion of tumor cells by triggering their suicide, while defects in apoptosis underpin both tumorigenesis and metastasis.¹⁰ Caspase-8 belongs to the caspase family of proteases and plays a key role in the regulation of apoptosis during normal development as well as in adult life. Since signaling via the death receptor (extrinsic) pathway critically depends on caspase-8, the distribution of caspase-8 expression or function may contribute to human diseases.¹¹

Cannabis (bhang, ganja, charas, hashish, kif, marijuana etc.) is one of the popular plants among common people since time immemorial due to its various uses and abuses. The hemp plant *Cannabis sativa* produces unique compounds known as cannabinoids (CND).¹² The most important cannabinoids found in the cannabis plant are tetrahydrocannabinol (Δ^9 THC) and cannabidiol (CBD). Cannabinoids have been shown to be effective in the treatment of nausea and vomiting

associated with cancer chemotherapy, anorexia and cachexia seen in HIV/AIDS patients, as well as neuropathic pain, and spasticity in multiple sclerosis.^{13,14}

Therefore, the aim of the present study was to evaluate the possible protective and therapeutic effects of Cannabis extract on dimethylnitrosamine-induced hepato-carcinogenicity in mice through studying TERT m-RNA, caspase-8 m-RNA gene expression levels, alanine transaminase (ALT), aspartate transaminase (AST) and gamma-glutamyl transpeptidase (γ -GT) activities.

2. Materials and methods

2.1. Preparation of plant extract

Cannabis sativa plant (the flowering tops of plants) was obtained by permission from the Public Prosecutor. One hundred gms of dry cannabis plant were minced into very small pieces and boiled with water for 5 min. The boiling water was discarded and the minced plant was left to dry at room temperature. Extraction was carried out by boiling the dried minced plant with 100 ml of ethyl alcohol for 10 min followed by filtration. The filtrate was transported into a specific apparatus used to evaporate cannabis residue by heating at specific temperatures (180–220 °C) to obtain cannabinoids free of some carcinogenic compounds (such as benzopyrene, benzene, toluene and naphthalene). The residue was heated up to 180 °C, the vapor was collected in petroleum ether (for trapping hydrocarbons) and then discarded. On raising the temperature from 180 °C to 220 °C the resulting vapor (contains cannabinoids) was received in methyl alcohol (trapping agent).¹⁵

Mass spectroscopy coupled with gas chromatography (GC/MS)¹⁶ was used as a method for detection of the received cannabinoids using column hp 5, capillary 30 m, GC type is Agilent 6890N, mass is Agilent 5973 N. Temperature program: start of 50 °C for 3 min, then temperature was increased at a rate of 50 °C/min up to 280 °C for 25 min. Injection temperature = 250 °C, detector temperature = 280 °C, injection volume = 3 μ l and wavelength λ = 50–550 M/Z (M = molecular weight, Z = charge). Methyl alcohol was evaporated and the cannabinoids' residue was dissolved in 100 ml of corn oil until time of use.

2.2. Animals and drug administration schedule

The experiments were conducted on seventy-five male mice weighing 20 ± 2 g and were housed in plastic cages at room temperature of 22 ± 1 °C under a 12 h light-dark cycle. The studies were carried out in accordance with the current ethical guidelines for investigation approved by the Ethics Committee of Medical Research Institute.

Animals were divided into five groups of 15 each. The groups were as follows: group I mice received corn oil only and served as the control group; group II mice were injected intraperitoneally with dimethylnitrosamine (DMNA 10 µg/kg body weight) weekly for 12 weeks;¹⁷ group III mice were pre-treated orally with cannabis extract (0.5 ml/kg body weight)¹⁸ every other day for two weeks before the intraperitoneal injection of DMNA, and continued until the end of the experiment (12 weeks); group IV mice were treated orally with cannabis extract (0.5 ml/kg body weight) every other day simultaneously with an intraperitoneal injection of DMNA and continued until the end of the experiment (12 weeks); group V mice were treated orally with cannabis extract (0.5 ml/kg body weight) every other day after receiving the last intraperitoneal injection of DMNA (12 weeks).

At the end of experiment, the mice were fasted overnight and then sacrificed under light ether anesthesia and the liver was divided into three parts:

- First part was used for total RNA extraction.
- Second part was used for liver tissue homogenate preparation.
- Third part was fixed in 10% formalin for histopathological examination.

2.3. Relative quantification of TERT mRNA and caspase-8 mRNA gene by real time PCR using SYBR green.^{19,20}

2.3.1. RNA extraction

Total RNA was extracted using Gene JET™ RNA Purification Kit (Fermentas) following the manufacturer's instructions and the standard protocol. RNA was detected by electrophoresis using a 1.0% agarose gel containing ethidium bromide (0.5 µg/ml) for 40 min at 100 V and the gel was observed under UV light. The eluted RNA was collected immediately, placed in ice or stored at -20 °C for further processing.

2.3.2. cDNA preparation

cDNAs were synthesized from the mRNA by high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) using a PCR thermocycler (Applied Biosystem). cDNA prepared for real time PCR was stored at -15 to -25 °C.

2.3.3. Real time PCR

For each sample, 5 µl cDNA was used for RT-PCR using the Power SYBR® Green RT-PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA) and the real time machine

(Applied Biosystems one step, Foster City, CA, USA) to detect relative expression levels of mTERT mRNA¹⁹ and caspase-8 mRNA.²⁰ The reaction conditions used to detect TERT and caspase-8 levels were: initial DNA denaturation at 95 °C for 10 min and then 40 cycles of denaturation at 95 °C for 15 s, annealing and elongation at 60 °C for 1 min. GAPDH (glyceraldehyde 3-phosphate dehydrogenase; housekeeping gene was used as an endogenous control) was included in each experiment.

2.3.4. Primers sequence

(Sigma-Aldrich Co., St. Louis, MO, USA) mTERT was (5'-ATGGCGTTCCTGAGTATGGGTGC-3') mTERT-forward and (5'-ACTTCAACCGCAAGACCGACAGG-3') mTERT-reverse.²¹

Caspase-8 was (5'-TCGCCCGAGCTGGAGTTGTGA-3') caspase-8-forward and (5'-CTCGGTTGCAGTCTAGGAA-GTTGA-3') Caspase-8-reverse.²⁰

GAPDH was (5'-ACCACAGTCCATGCCATCAC-3') GAPDH-forward and (5'-TCCACCACCCTGTTGCTGTA-3') GAPDH-reverse.²¹

The amount of target, normalized to an endogenous reference and relative to a calibrator, is given by $2^{-\Delta\Delta CT}$ where $CT =$ Threshold cycle. $\Delta CT = CT_t - CT_r$, where $\Delta CT =$ the difference in threshold cycles for target and reference.

$$\Delta\Delta CT = \Delta CT_{\text{cases}} - \Delta CT_{\text{calibrators}}$$

2.4. Biochemical analysis of hepatic liver enzymes

The liver was immediately removed, weighed, washed using chilled saline solution and homogenized (10% w/v) in 0.01 M sodium phosphate buffer (pH 7.4) in a Potter-elvehjem type homogenizer. The homogenate was centrifuged at $10,000 \times g$ for 20 min at 4 °C, and the resultant supernatant was used for ALT, AST and γ -GT levels determination using a kit (spectrum, Germany), according to the manufacturer's instructions. Enzyme activities were expressed in terms of U/L.

2.5. Histopathological examination

Liver tissues were fixed in 10% formalin, sectioned, and stained with hematoxylin and eosin (H and E).

2.6. Statistical analysis

Data were fed to the computer using IBM SPSS software package version 20.0. Quantitative data were described using mean and standard deviation. For normally distributed data, comparisons between different groups were analyzed using *F*-test (ANOVA) and Post Hoc test (Scheffe) for pair wise comparison. Significance test results are quoted as two-tailed probabilities. Significance of the obtained results was judged at the 5% level. A difference was considered significant at $p \leq 0.05$. Spearman's correlation coefficient was used to measure the closeness of a linear relationship between all parameters in all studied groups.

3. Results

3.1. Chromatography results

In Fig. 1, the GC chromatogram showed that the retention times of cannabis vapor extract constituents are 7.03 and 7.44 min, identical to the retention times of Δ^9 THC and

CBD standards, respectively. The relative amounts are 67.9% for Δ^9 THC and 32.1% for CBD. The phenotype ratio of cannabis extract = THC%/CBD% = 67.9%/32.1% > 1.

GC/MS allows positive identification of Δ^9 THC and CBD in cannabis vapor extract which is shown in Fig. 2(A and B) with base peaks at 231 for each constituent.




Figure 1 GC chromatogram of cannabis vapor extract.




Figure 2 GC/MS chromatograms showing that the cannabis vapor extract contains (A) Δ^9 THC and (B) cannabidiol.

3.2. Molecular and biochemical results

The amplification plots of fluorescence intensity against the PCR cycle from tissue samples and melting curves of both TERT mRNA and caspase-8 mRNA are shown in Figs. 3 and 4 respectively.

The mTERT expression level was significantly increased in group II as compared to the control group ($p_1 < 0.001$). The gene level in groups (III, IV, and V) was insignificantly higher than the control group ($p_1 = 1.000, 1.000, \text{ and } 0.952$ respectively) but it was significantly decreased as compared to group II ($p_2 < 0.001$). The mTERT expression in groups (IV, V) did not show any significant difference when compared with group III ($p_3 = 1.000, 0.971$ respectively) or with each other ($p_4 = 0.981$) (Table 1).

The caspase-8 expression level was significantly decreased in all groups as compared to the control group ($p_1 < 0.001$). As compared to group II, caspase-8 expression level was significantly increased in group III ($p_2 = 0.031$), while in groups IV and V it did not show any significant difference ($p_2 = 0.992, 1.000$ respectively). As compared to group III, caspase-8 expression level in group IV did not show any significant difference ($p_3 = 0.098$), while in group V it was significantly decreased ($p_3 = 0.038$). Group V did not show any significant difference when compared with group IV ($p_4 = 0.996$) (Table 1).

ALT and AST activities were significantly decreased in all groups as compared to the control group ($p_1 < 0.001$) and significantly increased in groups (III, IV and V) as compared to group II ($p_2 < 0.001$). As compared to group III, ALT activity was significantly decreased in group IV ($p_3 = 0.001$), while in group V it did not show any significant difference ($p_3 = 0.998$). In group V, the ALT activity was significantly higher than in group IV ($p_4 = 0.002$). AST activity in groups (IV and V) did not show any significant difference when compared

with group III ($p_3 = 0.131, 0.752$ respectively) or with each other ($p_4 = 0.752$) (Table 1).

The γ -GT activity was significantly increased in all groups as compared to the control group ($p_1 < 0.001$) while it was significantly decreased in groups (III, IV and V) as compared to group II ($p_2 < 0.001$). As compared to group III, γ -GT activity was significantly increased in group IV ($p_3 = 0.008$), while in group V it did not show any significant difference ($p_3 = 0.721$). γ -GT activity was significantly decreased in group V as compared to group IV ($p_4 = 0.013$) (Table 1).

There was a significant positive correlation between ALT, AST ($r = 0.951, p \leq 0.001$) and caspase-8 gene expression and also between γ -GT activity and TERT gene expression. The significant negative correlation between γ -GT and each of ALT ($r = -0.886, p < 0.001$), AST activities ($r = -0.883, p < 0.001$), and caspase-8 gene expression was observed and also between TERT gene expression and the activities of both ALT and AST (Fig. 5A and B).

3.3. Histopathological results

Group I: showed normal hepatic architecture with no evidence of inflammation, fibrosis, necrosis, neoplasia or dysplasia (Fig. 6).

Group II: Receiving DMNA: All hepatic sections showed well to moderately differentiated HCC. Trabeculae several cells thick are seen lined by pleomorphic hepatocytes with hyperchromatic nuclei and abnormal mitotic figures. The stroma was scantily formed of sinusoidal vessels. Necrosis when present was always focal and there was no fibrosis (Fig. 7).

Group III: Cannabis before DMNA: All cases developed well to moderately differentiated HCC. Signs of tumor regression were present in the form of frequent apoptotic hepatocytes with condensed pyknotic nuclei surrounded by




Figure 3 (A) Amplification plot and (B) melting curves of TERT m-RNA for all the studied groups, where A is group I, B is group II, C is group III, D is group IV and E is group V.




Figure 4 (A) Amplification plot and (B) melting curves of caspase-8 m-RNA for all studied groups.

perinuclear halo. Wide areas of necrosis were seen with secondary infiltration by acute and chronic non-specific inflammatory cells (Fig. 8).

Group IV: Cannabis plus DMNA: All cases developed HCC of well differentiated morphology. Coagulative necrosis

and scattered apoptotic hepatocytes and bodies characterized this group (Fig. 9).

Group V: Cannabis after DMNA: All cases showed well to moderately differentiated HCC. The majority of cases showed viable tumor with occasional spotty foci of coagulative

Table 1 Hepatic TERT mRNA, caspase-8 m-RNA expression level (copies), ALT, AST and γ -GT activities (U/L) for all studied groups.

Groups	TERT mRNA expression level (copies)	Caspase-8 mRNA expression level (copies)	ALT activity (U/L)	AST activity (U/L)	γ -GT activity (U/L)
Control (gp I)	1.22 \pm 0.62	1.08 \pm 0.41	345.47 \pm 13.06	434.8 \pm 23.58	5.02 \pm 0.12
DMNA (gp II)	116.13 \pm 61.47 ^a	0.11 \pm 0.04 ^a	139.87 \pm 8.20 ^a	205.0 \pm 12.49 ^a	8.21 \pm 0.49 ^a
Cannabis before DMNA (gp III)	2.29 \pm 1.52 ^b	0.35 \pm 0.12 ^{a,b}	285.93 \pm 11.93 ^{a,b}	362.33 \pm 19.88 ^{a,b}	6.54 \pm 0.24 ^{a,b}
Cannabis plus DMNA (gp IV)	3.08 \pm 4.25 ^b	0.15 \pm 0.09 ^a	265.93 \pm 11.93 ^{a,b,c}	342.33 \pm 19.88 ^{a,b}	7.12 \pm 0.31 ^{a,b,c}
Cannabis after DMNA (gp V)	9.60 \pm 7.0 ^b	0.12 \pm 0.04 ^{a,c}	284.40 \pm 13.30 ^{a,b,d}	352.53 \pm 23.22 ^{a,b}	6.70 \pm 0.26 ^{a,b,d}

Statistically significant at $p \leq 0.05$.

ANOVA test used for comparing between the different studied groups.

Number for each group (n) = 15.

^a Comparing with control group (I).

^b Comparing groups III, IV, V with group II.

^c Comparing groups IV, V with group III.

^d Comparing group V with group IV.




Figure 5 Correlation between (A) mTERT and (B) caspase-8 mRNA for each ALT, AST and GGT.

necrosis and moderate number of apoptotic cells and bodies (Fig. 10).

4. Discussion

The most important mechanism of liver cancer progression is cell proliferation. Although in recent years several clinical trials have tested the efficacy of agents that selectively target important signaling pathways involved in the control of this process, no relevant improvement in the prognostic/survival of patients with HCC has been achieved so far, and, therefore, it is necessary to identify novel therapeutic strategies for the management of HCC.²²

Cannabis vaporization is a relatively new technology aimed at suppressing respiratory toxins (e.g. benzopyrene, naphthalene, benzene and toluene) by heating cannabis to temperatures below the point of combustion when smoke and associated toxins are produced (near 230 °C). The electric vaporizer can successfully generate THC at 185 °C while completely suppressing toxins.^{23,24}

The results obtained from the chromatograms indicate that the cannabis vapor extract consists of 67.9% of Δ^9 THC and 32.1% of CBD free from hazardous compounds. The phenotype ratio of cannabis plant, where cannabis preparation with ratio greater than 1.0, is classified as the drug phenotype or biologically active or more precisely as Δ^9 THC phenotype.




Figure 6 (Control group) showing normal hepatic architecture (H&E $\times 400$).




Figure 7 (Group II) showing well differentiated HCC with foci of necrosis (H&E $\times 400$).




Figure 8 (Group III) moderately differentiated HCC showing frequent apoptotic figures (H&E, $\times 400$).

However, that is with a ratio smaller than 1.0 classified as fiber phenotype or non-biologically active or cannabidiol phenotype.²⁵




Figure 9 (Group IV) HCC showing necrosis (center) and apoptotic bodies (arrows) (H&E, $\times 400$).




Figure 10 (Group V) HCC showing frequent apoptotic bodies (fragmented chromatin) (H&Estain, $\times 400$).

The relative amounts in cannabis vapor extract give a drug phenotype or more precisely Δ^9 THC phenotype. Where the phenotype ratio of cannabis extract = THC% content/CBD% = 67.9%/32.1% > 1.

The investigation of the therapeutic effects of cannabinoids on some cancer-related disorders has provided evidence of their effectiveness in the alleviation of several symptoms observed in cancer patients, such as appetite loss and neuropathic pain.²⁶ Beyond the palliative effects induced by these compounds, previous advances in the knowledge of the biological role of endocannabinoids and novel insights into the molecular signaling of cannabinoid receptors, support the participation of the endocannabinoid system in the regulation of key processes involved in the development of cancer.^{27,28} So this study aimed to evaluate the possible protective and therapeutic effects of cannabis extract on DMNA-induced hepatocarcinogenicity in mice.

In this study, there was a significant increase in the expression of TERT mRNA in the DMNA group (group II) as compared to the control group. The higher increase of TERT mRNA level in the DMNA group was in parallel to that reported by Braicu et al.²⁹ and Miura et al.³⁰ Although telomerase is not carcinogenic, it plays a direct role in oncogenesis by allowing the precancerous cells to proliferate continuously and

become immortal. These results were confirmed by the histopathological findings in the control group, and DMNA group.

Telomerase has been found to be expressed in most immortal cell lines, but it was undetectable in adult normal tissues, so in malignant tumors telomerase is thought to be activated to maintain their immortality. It has been suggested that telomerase is one of the critical steps in malignant transformation and its strong enhancement considered an important part of hepatocarcinogenesis.³¹

On the other hand, there was a significant decrease in the expression of TERT mRNA in groups III, IV, and V as compared to group II. These results may be due to the protective effect of the pretreatment and therapeutic effect of (simultaneous and post-treatment) cannabis extract. Vara et al.³² study of cannabinoids on HCC showed that Δ^9 -THC and JWH-015 (synthetic cannabinoids) efficiently reduced ascites development and alpha fetoprotein (AFP) expression in HCC, which also paralleled mammalian target of rapamycin C1 (mTORC1) inhibition, adenosine monophosphate-activated kinase (AMPK) activation and autophagy stimulation in those tumors. Their data represent the first evidence for the anti-proliferative action of cannabinoids in HCC cells *in vivo* and support that the ability of cannabinoids to inhibit mTORC1, stimulate AMPK and enhance autophagy could be therapeutically exploited for the management of HCC. In addition, the ability of THC to reduce inflammation (a pro-tumorigenic function of the immune system), and this effect may seem to be beneficial for preventing certain types of cancer.³³

Our findings suggested that the treatment with cannabis extract inhibits TERT mRNA expression level which leads to down regulation of telomerase activity.

In the current work, TERT mRNA expression level in groups III, VI and V showed insignificant change when compared with each other. This insignificant difference may be attributed to cannabinoid treatment, where cannabinoids impair tumor progression at different levels through the inhibition of cancer cell proliferation. These results are in line with *in vivo* experiments which indicated that cannabinoids impair tumor angiogenesis and block invasion and metastasis.³⁴

These results are confirmed by the histopathological study which revealed that the liver shows frequent apoptotic hepatocytes with condensed nuclei and wide areas of necrosis in group III, spotty coagulative necrosis in group IV and coagulative necrosis in group V.

In the present study, there was a significant decrease in the expression of caspase-8 mRNA in groups II, III, IV and V as compared to the control group. The lower level of caspase-8 mRNA expression in the DMNA group was in agreement with previous studies which found that caspase-8 is frequently silenced by promoter hypermethylation indicating that tumorigenesis is associated with inactivation of caspase-8.^{35,36}

Caspase-8 is a key signaling molecule of apoptosis, loss of caspase-8 expression or function has a profound impact on the cancer cell's ability to undergo apoptosis. Various mechanisms including genetic, epigenetic and posttranslational alterations have been identified that cause inactivation of this central apoptosis regulator in human cancers.¹¹ Loss or dysfunction of caspase-8 results in increased cellular transformation, enhanced tumor progression, poor response to chemotherapy, and impaired prognosis of patients of different cancer entities.^{37,38}

On the other hand, there was a significant increase in the expression of caspase-8 mRNA in group III as compared to the corresponding values in group II. Our results may be due to the administration of cannabis plant extract as a protective treatment. These results were in agreement with a previous study of Lombard and his associates³⁹ which showed that THC treatment of the cells led to the activation of caspases 2, 8, 9, and 10 in that order, and cleavage of Bid occurred 2 h after treatment. Overall, these studies demonstrated that THC-induced apoptosis was occurring through cross-talk between the extrinsic and intrinsic pathways, with the intrinsic pathway playing the primary role. Also, Giuliano et al.⁴⁰ found that modulation of both cannabinoid receptors by some synthetic cannabinoids induces apoptosis in a hepatocellular carcinoma cell line.

The most prevalent effect of cannabinoids is the induction of cancer cell death by apoptosis and the inhibition of cancer cell proliferation. At least one of these actions has been demonstrated in almost all the cancer cell types tested.³⁴

This study revealed that, there was no significant change in caspase-8 mRNA expression level in groups IV and V as compared to group II as well as in group IV as compared to group III, while it was significantly decreased in group V as compared to group III. These results may be due to that, the percentage of apoptotic cells after treatment was increased both in a time-dependent manner and in a dose-dependent manner.⁴¹

Our study demonstrated that there was a significant decrease in the hepatic activities of both ALT and AST in groups II, III, IV, and V as compared to the control group. DMNA induces liver fibrosis in a highly reproducible manner, first inducing a central hemorrhagic necrosis followed by the formation of septa and establishing micronodular cirrhosis after 3 weeks of treatment.⁴² Lower hepatic AST and ALT activities might be attributed to the damage of the liver tissue due to the alteration of the membrane components in the tissue, resulting in the release of these enzymes into the blood.⁴³ We suggested that the decrease in the hepatic activities of AST and ALT in our results has been positively correlated with the increased liver damage.

The hepatic activities of ALT and AST were significantly increased in groups III, IV, and V as compared to group II, but still significantly decreased as compared to the control group. This partial improvement in the enzyme activities may be due to the protective effect of the pretreatment and therapeutic effect of (simultaneous and post-treatment) cannabis extract, in addition to non toxicity of the cannabis extracts in the liver tissue.¹³ Also, cannabidiol pretreatment significantly attenuated the elevations of serum aminotransferases, decreased oxidative and nitrate stress, and reduced the inflammatory response in the liver tissue. The antioxidant, anti-inflammatory and antiapoptotic activities can be considered the main factors responsible for the hepatoprotective effect of cannabidiol. Therefore, cannabidiol may be a feasible therapeutic candidate to prevent liver tissue injury.⁴⁴

In the present study there was a significant increase in the hepatic activity of γ -GT in groups II, III, IV, and V as compared to the control group. These results are in agreement with a previous study.⁴⁵ The elevated values of γ -GT activity in their study are an indication of parenchymal cell damage and induction of hepatic necrosis and premalignant hepatocellular damage induced by DMNA administration. γ -GT is the most sensitive indicator of hepatobiliary disease.⁴⁶

The activities of γ -GT are rather low in normal liver tissues, expressed mainly on the border of epithelial cell membrane of biliary duct and intrahepatic cholangioles with strong secretory and absorptive functions. With the feature of carcinoembryonic protein, hepatoma-related γ -GT is produced and secreted when the genes controlling γ -GT synthesis were expressed abnormally. Hence γ -GT is usually considered as the early enzyme marker of hepatocarcinogenesis.⁴⁷ These results were confirmed by the histopathological study which revealed that the liver showed well differentiated HCC with foci of necrosis in group II.

On the other hand, there was a significant decrease in γ -GT activity in groups III, IV, and V as compared to group II. These results may be due to the protective and therapeutic effects of cannabis extract. Numerous studies show that THC and other cannabinoids exhibit anti-tumor effects on a wide range of animal models of cancer.^{13,48} Administration of cannabinoids to tumor-bearing mice decreased the activity and expression of matrix metalloproteinase-2 (a proteolytic enzyme that allows tissue breakdown and remodeling during angiogenesis and metastasis).⁴⁹

The obtained results were confirmed by the correlation study, which indicated that there was a significant positive correlation between ALT, AST activities and caspase-8 gene expression and also between γ -GT activity and TERT gene expression. In addition the significant negative correlation between γ -GT activity and each of ALT, AST activities, caspase-8 gene expression and also between TERT gene expression and the activities of both ALT and AST. These results may be due to that hepatic injury, cellular leakage and loss of the functional integrity of the liver cell membrane induced by DMNA lead to decreasing levels of ALT, AST activities, and caspase-8 gene and increasing levels of both TERT gene expression and γ -GT activity.

In conclusion, exposure to DMNA plays a role in pathogenesis of liver disease leading to carcinogenicity and causes disturbances in the activities of mice liver enzymes while cannabis causes a partial improvement in these enzymes. The protective effect of cannabis extract is more pronounced than other groups and this is demonstrated in group III. Cannabinoids might exert their anti-tumor effects by direct induction of apoptosis and can decrease telomerase activity by inhibiting the expression of hTERT gene. Coordination between inhibition of telomerase activity and induction of apoptosis might be a potential therapeutic agent for cancer treatment.

It is widely believed that strategies that aim to reduce mortality from cancer should consist of targeted therapies that are capable of providing the most efficacious and selective treatment for each individual tumor and patient.

Conflict of interest

We have no conflict of interest to declare.

References

- Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. *Nat Rev Gastroenterol Hepatol* 2010;**7**:448–58.
- Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. *Expert Rev Gastroenterol Hepatol* 2009;**3**:353–67.
- Caldwell SM, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. *Gastroenterology* 2004;**127**:97–103.
- Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2005;**17**:477–83.
- Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinoma. *Nat Genet* 1998;**18**:65–8.
- Shimajima M, Komine F, Hisatomi H, Shimizu T, Moriyama M, Arakawa Y. Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. *Hepatol Res* 2004;**29**:31–8.
- Chang MW, Grillari J, Mayrhofer C, Fortschegger K, Allmaier G, Marzban G, et al. Comparison of early passage, senescent and hTERT immortalized endothelial cells. *Exp Cell Res* 2005;**309**:121–36.
- Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994;**266**:2011–5.
- Zhang C, Tian YP, Wang Y, Guo FH, Qin JF, Ni H. hTERT rs2736098 genetic variants and susceptibility of hepatocellular carcinoma in the Chinese population: a case-control study. *Hepatobiliary Pancreat Dis Int* 2013;**12**:74–9.
- Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nat Rev Cancer* 2006;**6**:449–58.
- Fulda S. Caspase-8 in cancer biology and therapy. *Cancer letters* 2009;**281**:128–33.
- Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. *J Ethnopharmacol* 2006;**105**:1–25.
- Guzman M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer* 2003;**3**:745–55.
- Pollmann W, Fenenberg W. Current management associated with multiple sclerosis. *CNS Drugs* 2008;**22**:291–324.
- Richard E. Cannabis, “Vaporization”: a promising strategy for smoke. *J Cannabis Therapeutic* 2001;**1**:3–4.
- Harvey DJ. Comparison of fourteen substituted silyl derivatives for the characterization of alcohols, steroids and cannabinoids by combined gas–liquid chromatography and mass spectrometry. *J Chromatogr* 1978;**147**:291–8.
- Souliotis VL, Henneman JR, Reed CD, Chhabra SK, Diwan BA, Anderson LM. DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis. *Mutat Res* 2002;**500**:75–87.
- Sheweita S. Narcotic drugs changes the expression of cytochrome p450 2E1, 2C6 and other activities of carcinogen metabolizing in the liver of male mice. *Toxicology* 2003;**191**:133–42.
- El-Fadle AA, Al Hussein NF, El-kholy AF, Al-Said O, Al-Toukhy N, Atta MM. Telomerase reverse transcriptase gene expression as a tumor marker for hepatocellular carcinoma. *Am J Biochem Biotech* 2011;**7**:55–62.
- Zhang X, Zheng X, Sun H, Feng B, Chen G, Vladau C, et al. Prevention of renal ischemic injury by silencing the expression of renal caspase-3 and caspase-8. *Transplantation* 2006;**82**:1728–32.
- Ritz JM, Kuhle O, Riethdorf S, Sipos B, Deppert W, Englert C, et al. A novel transgenic mouse model reveals humanlike regulation of an 8-kbp human TERT gene promoter fragment in normal and tumor tissues. *Cancer Res* 2005;**65**:1187–96.
- Duffy A, Gretten T. Developing better treatments in hepatocellular carcinoma. *Expert Rev Gastroenterol Hepatol* 2010;**4**:551–60.
- Polen M. Health care use by frequent marijuana smokers who do not smoke tobacco. *West J Med* 1993;**158**:596–601.
- Tashkin D. Is frequent marijuana smoking hazardous to health? *West J Med* 1993;**158**:635–7.
- Waller CW, Scigliano JA. The national marihuana program. Report to commission on problems of drug dependence. *Nat Acad Sci N R C* 1970;**4**:28–32.

26. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, palliation. *Lancet Oncol* 2005;**6**:35–42.
27. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* 2005;**5**:400–11.
28. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerri P, Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. *J Cell Physiol* 2007;**211**:495–503.
29. Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Graur F. Hepatocellular carcinoma. Tumorigenesis prediction markers. *Gastroenterol Res* 2009;**2**:191–9.
30. Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, et al. A novel biomarker TERT mRNA is applicable for early detection of hepatoma. *BMC Gastroenterol* 2010;**10**:46.
31. Takumay E, Nouse K, Kobayashi Y, Nakamura S, Tanaka H, Matsumoto E, et al. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma. *J Gastroenterol Hepatol* 2004;**19**:1300–4.
32. Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Diaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. *Cell Death Differ* 2011;**18**:1099–111.
33. Liu WM, Fowler DW, Dalglish AG. Cannabis-derived substances in cancer therapy – an emerging anti-inflammatory role for the cannabinoids. *Curr Clin Pharmacol* 2010;**5**:281–7.
34. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 2012;**12**:436–44.
35. Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, et al. Caspase-8 gene is frequently inactivated by the frame shift somatic mutation 1225 1226delTG in hepatocellular carcinomas. *Oncogene* 2005;**24**:141–7.
36. Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, et al. Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. *Gastroenterology* 2005;**129**:1602–15.
37. Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. *Blood* 2006;**108**:1050–7.
38. Mata JF, Silveira VS, Mateo EC, Cortez MA, Queiroz RG, Yunes JA, et al. Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL). *Pediatr Blood Cancer* 2010;**55**:100–7.
39. Lombard C, Nagarkatti M, Nagarkatti PS. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in delta9-tetrahydrocannabinol (thc)-induced apoptosis of jurkat cells. *Leuk Res* 2005;**29**:915–22.
40. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, et al. Apoptosis induced in hepg2 cells by the synthetic cannabinoid win: Involvement of the transcription factor PPAR gamma. *Biochimie* 2009;**91**:457–65.
41. Qing-You Du, Wang Xiao-Bo, Chen Xue-Jun, Zheng Wei, Wang Sheng-Qi. Anti-tumor mechanism of antisense canteide targeting human telomerase reverse transcriptase. *W J Gastroenterol* 2003;**9**:2030–5.
42. Jin YL, Enzan H, Kuroda N, Hayashi Y, Toi M, Miyazaki E, et al. Vascularization in tissue remodeling after rat hepatic necrosis induced by dimethylnitrosamine. *Med Mol Morphol* 2006;**3**:33–43.
43. Oluduro AO, Aderiye BI. Effect of *Moringa oleifera* seed extract on vital organs and tissue enzymes activities of male albino rats. *African J Microbiol Res* 2009;**3**:537–40.
44. Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanashia G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic Biol Med* 2011;**50**:1368–81.
45. Priya S, Vijayalakshmi P, Vivekanandan P, Karthikeyan S. Influence of N-acetylcysteine against dimethylnitrosamine induced hepatotoxicity in rats. *Toxicol Ind Health* 2011;**27**:914–22.
46. Vasudevan DM, Sreekumari S, Vaidyanathan Kannan. *Text Book of Biochemistry for Medical Students*. third ed. New Delhi: Japee Brothers Medical Publishers (P) Ltd.; 2001.
47. Qi-Yun T, Deng-Fu Y, Jian-Xin L, Xin-Hua W, Xian-Yong M. Expression and alterations of different molecular form γ -glutamyl transferase and total RNA concentration during the carcinogenesis of rat hepatoma. *W J Gastroenterol* 1999;**5**:356–8.
48. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. *Cancer Res* 2008;**68**:339–42.
49. Blázquez C, Casanova ML, Planas A, Gómez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, et al. Inhibition of tumor angiogenesis by cannabinoids. *FASEB J* 2003;**17**:529–31.